Utility of Suprasternal Transinnominate Artery for Alternate Access in Transcatheter Aortic Valve Replacement.

OBJECTIVE: Despite advancements in transcatheter aortic valve replacement (TAVR) technology, alternate access strategies are still required when transfemoral access is unsuitable. In these often anatomically complex group of patients, we sought to evaluate the safety and feasibility of suprasternal transinnominate (TI) artery access for TAVR. METHODS: At our institution, 652 patients underwent TAVR from November 2011 through February 2020. Of these, 23 patients underwent TI TAVR via a 5-cm suprasternal incision without special instrumentation. Outcomes of interest were technical considerations, postoperative complications, and perioperative recovery in relation to established access strategies. RESULTS: The mean Society of Thoracic Surgeons risk score was 8.6 ± 4.2 and the average age was 75 ± 8. All patients underwent TI TAVR using a self-expanding (12), or balloon-expandable (11) transcatheter heart valve. Average postoperative stay was 2 ± 0.7 days (range 2 to 4) with most 20/23 (87%) being discharged to home. There was no 30-day mortality or readmission. There was 1 access-site complication and 1 cerebrovascular accident within 30 days, both intraoperative, with excellent recovery. All patients had either trivial (19) or mild (4) aortic regurgitation on 30-day echocardiography. CONCLUSIONS: TAVR via suprasternal TI access is feasible, safe, provides satisfactory perioperative recovery and adds to the options when patients require alternate access. Further data would be optimal to validate this single-center experience.

1-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification.

BACKGROUND: The risk of surgical mitral valve replacement in patients with severe mitral annular calcification (MAC) is high. Several patients worldwide with severe MAC have been treated successfully with transcatheter mitral valve replacement (TMVR) using balloon-expandable aortic transcatheter valves. The TMVR in MAC Global Registry is a multicenter registry that collects data on outcomes of these procedures. OBJECTIVES: The goal of this study was to evaluate 1-year outcomes in this registry. METHODS: This study was a multicenter retrospective review of clinical outcomes. RESULTS: A total of 116 extreme surgical risk patients with severe MAC underwent TMVR; 106 had a procedure date >1 year before data-lock and were included in the analysis. Their mean age was 73 ± 12 years, and 68% were female. The mean Society of Thoracic Surgeons score was 15.3 ± 11.6%, and 90% were in New York Heart Association functional class III or IV. Thirty-day and 1-year all-cause mortality was 25% and 53.7%, respectively. Most patients who survived 30 days were alive at 1 year (49 of 77 [63.6%]), and the majority (71.8%) were in New York Heart Association functional class I or II. Echocardiography data at 1 year were available in 34 patients. Mean left ventricular ejection fraction was 58.6 ± 11.2%, mean mitral valve area was 1.9 ± 0.5 cm2, mean mitral gradient was 5.8 ± 2.2 mm Hg, and 75% had zero or trace mitral regurgitation. CONCLUSIONS: TMVR with balloon-expandable aortic valves in extreme surgical risk patients with severe MAC is feasible but associated with high 30-day and 1-year mortality. Most patients who survive the 30-day post-procedural period are alive at 1 year and have sustained improvement of symptoms and transcatheter valve performance. The role of TMVR in patients with MAC requires further evaluation in clinical trials.

Video-assisted epicardial ablation and left atrial appendage exclusion for atrial fibrillation: extended follow-up.

BACKGROUND: New ablation technologies have spurred development of less invasive operations for atrial fibrillation. The long-term efficacy of these procedures is unknown. METHODS: This was a retrospective study of 22 patients aged 63 +/- 9 years with symptomatic, intermittent atrial fibrillation who underwent video-assisted, thoracoscopic pulmonary vein isolation and left atrial appendage exclusion from April 2004 through July 2005. The procedure consisted of bilateral 10-mm ports and 5-cm non-rib-spreading working ports. The left atrial appendage was excised with a surgical stapler. All patients were followed for at least 1 year, and all underwent Holter monitoring at study end point. RESULTS: The procedure was performed safely in all patients. One patient did not undergo left atrial appendage excision because of preexisting adhesions. No stroke, reoperation for bleeding, or patient mortality occurred. Average hospital stay was 3.2 +/- 2.0 days (range, 2 to 10 days). No patient required repeat atrial fibrillation ablation. One patient underwent right atrial flutter ablation 7 months postoperatively. Average follow-up time was 18.1 +/- 4.1 months (range, 12 to 27 months). At the end of follow-up, 20 patients (91%) were free of symptoms without antiarrhythmic therapy. Holter monitoring in these patients (performed more than 6 months after cessation of antiarrhythmic drugs) showed sinus rhythm and no atrial fibrillation. Twenty patients (91%) were no longer taking warfarin at the end of the study period. CONCLUSIONS: Bilateral, video-assisted, thoracoscopic pulmonary vein isolation with left atrial appendage exclusion has favorable single-procedure efficacy after extended follow-up for selected patients with atrial fibrillation.

Adjunctive atrial fibrillation therapy with off-pump coronary artery bypass grafting: standard of care?

OBJECTIVES: : To validate the safety and applicability of a previously unreported innovative technique: bipolar epicardial radiofrequency pulmonary vein ablation for the treatment of atrial fibrillation (AF) in conjunction with off-pump coronary artery bypass surgery. METHODS: : After the completion of off-pump coronary artery bypass grafting (OPCAB) via sternotomy, patients underwent epicardial pulmonary vein ablation using a bipolar radiofrequency clamp placed on the left atrial cuff. The left atrial appendage was removed or excluded in all patients. RESULTS: : Fifteen patients (aged 59-81 years) were treated and reviewed. An average of 2.8 ± 1 grafts were performed per patient; all patients received left internal mammary artery grafts. All sets of pulmonary veins were encircled successfully and ablated. Four patients had additional lesions placed. No patient had pulmonary vein injury. There were no reoperations for bleeding and no mortality. Preoperatively, AF was continuous in 4 patients and intermittent in 11; 10 patients were taking Coumadin preoperatively and 11 were taking antiarrhythmic drugs (AAD). At the follow-up evaluation (7.6 ± 4.4 months; range 1-16 months), 12 patients (80%) are in sinus rhythm (100% in the intermittent AF group, 25% in the continuous AF group); Coumadin has been discontinued in 5 of 10 patients (50% reduction) and AAD have been discontinued in 7 of 11 patients (74% reduction). CONCLUSIONS: : Bipolar radiofrequency epicardial pulmonary vein ablation can be safely and reproducibly used for the treatment of AF in conjunction with OPCAB. Patients with intermittent AF should be strongly considered for adjunctive treatment at the time of OPCAB.

Intraoperative effects of the coapsys annuloplasty system in a randomized evaluation (RESTOR-MV) of functional ischemic mitral regurgitation.

BACKGROUND: Functional ischemic mitral regurgitation (MR) frequently arises after myocardial infarction; it is characterized by annular enlargement or lateral displacement of the subvalvular apparatus. Coapsys is a ventricular-annular remodeling device designed to treat functional ischemic MR; it does not require cardiopulmonary bypass. Initial intraoperative results of the RESTOR-MV randomized clinical trial are presented. METHODS: Patients referred for coronary artery bypass grafting with preoperative MR grade of 2 or greater were studied, excluding those with structural valve abnormalities. The Coapsys device, which consists of two epicardial pads connected by a flexible cord, was surgically implanted in 19 patients. Under epicardial echocardiographic guidance, the cord was passed through the left ventricle and tightened externally to improve leaflet coaptation and stabilize the ventricular wall; tightening was conducted with color flow Doppler imaging. RESULTS: Patients were 64.5 +/- 9.2 years old with an ejection fraction of 0.383 +/- 0.089 and received 2.7 +/- 1.1 grafts. Intraoperative MR grade was 2.7 +/- 0.8 after induction and was reduced to 0.4 +/- 0.7 after implantation (p < 0.0001). Mean epicardial dimension was reduced from 8.5 +/- 1.2 to 6.4 +/- 0.9 cm (p < 0.0001). Intraoperative MR was reduced in 95% (18 of 19) of patients, and 84% (16 of 19) had MR grade 1 or less after implantation. All implants were performed without cardiopulmonary bypass or conversion to standard annuloplasty. No hemodynamic compromise or structural damage to the mitral apparatus was noted. Significant acute remodeling was noted in the left ventricular dimensions. CONCLUSIONS: In patients without structural valve disease, the Coapsys device acutely reduces functional MR. Further randomized evaluation will assess long-term stability and compare it with standard annuloplasty techniques.